Abstract
In order to identify the structural requirement at 4-position of 1-arylsulfonyl-4-phenyl-4,5-dihydro-2-limidazolones3 for their cytotoxicity, the corresponding 1-arylsulfonyl-4-cyclohexyl-4,5-dihydro-2-imidazolones4 were synthesized and theirin vitro cytotoxicity against human solid tumor cell lines were measured. Unlike compounds3a-c, cyclohexyl analogues4a-c do not show the cytotoxicity. This dramatic loss of activity of these analogues on the volume change with the bulkier cyclohexyl group indicates that the planar structure at 4-position of 1-arylsulfonyl-4-phenyl-4,5-dihydro-2-limidazolones3 is required for their activity as an important pharmacophoric moiety.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Everitt, E. and Wohlfart, C., Spectrophotometric quantitation of anchorage-dependent cell numbers extraction of naphthol blue-black-stained cellular protein.Anal. Biochem., 162(1), 122–9 (1987).
Grindey, G. B., Boder, G. B., Grossman, C. S., Howbert, J. J., Poore, G. A., Shaw, W. H., Todd, G. C., and Worzalla, J. F., Further development of diarglsulfonylureas as novel anticancer drugs.Proc. Am. Assoc. Cancer Res., 28, 309 (1987).
Grindey, G. B., Identification of diarysulfonylureas as novel anticancer drugs.Proc. Am. Assoc. Cancer Res., 29, 535 (1988).
Grindey, G. B., Current status of cancer drug development: Failure or limited success.Cancer Cells, 2, 163–171 (1990).
Hainsworth, J. D., Handle, K. R., Satterlee, W. G., Kuttesch, J., Johnson, D. H., Grindey, G. B., Jackson, L. E., and Greco, F. A., Phase I clinical study of N-[(4-chlorophenylamino)]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).Cancer Res., 49, 5217–5220 (1989).
Hansch, C., Leo, A.,Exploring QSAR, ACS Professional Reference Book, American Chemical Society, Washington, DC, U. S. A., 1995, pp. 522–528.
Houghton, P. J., Bailey, F. C., Germain, G. S., Grindey, G. B., Witt, B. C. and Houghton, J. A., N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea, A novel agent equally cytotoxic to nonproliferlating human colon adenosarcoma cells.Cancer Res., 50, 318–322 (1990).
Houghton, P. J., Bailey, F. C., Houghton, J. A., Murti, K. G., Howbert, J. J. and Grindey, G. B., Evidence for mitochondrial localization of N-(4-Methylphenylsulfonyl)-N′-(4-chlorophenyl) urea in human colon adenosarcoma cells.Cancer Res. 50, 664–668 (1990).
Howbert, J. J., Grossman, C. S., Crowell, T. A., Rieder, B. J., Harper, R. W., Kramer, K. E., Tao, E. V., Aikins, J., Poore, G. A., Rinzel, S. M., Grindey, G. B., Shaw, W. N., Todd, G. C., Novel Agents Effective against Solid Tumors: The Diarylsulfonylureas. Synthesis, Activities, and Analysis of Quantitative Structure-Activity Relationships.J. Med. Chem., 33, 2393–2407 (1990).
Howbert, J. J., Sulofenur.Drugs Future., 16, 517–520 (1991).
Jung, S. H., Song, J. S., Lee, H. S., Choi, S. U., and Lee, C. O., Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones.Bioorg. Med. Chem. Lett. 6, 2553–2558 (1996).
Jung, S. H., Song, J. S., Lee, H. S., Choi, S. U., and Lee, C. O., Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones containing sulfonylurea pharmacophore.Arch. Pharm. Res., 19, 570–580 (1996).
Kamthan, A., Scarffe, J. H., Walling, J., Hatty, S., Peters, B., Coleman, R., and Smyth, J. F., A phase II study of solufenur (LY186641) in gastric cancer.Anti-cancer Drugs, 3, 331–335 (1992).
Munshi, N. C., Seitz, D. E., Fosella, F., Lippman, S. N., and Einhorn, L. H., Phase II study of sulofenur (LY186641). A novel antineoplastic agent in advanced non-small lung cancer.Proc. Am. Assoc. Cancer Res. 32, 189 (1991).
Perrin, D. D., Armarego, W. L. F., and Perrin, D. R.,Purification of laboratory chemicals, 2nd edition. Pergamon Press, Oxford, England, 1982.
Schultz, R. M., Merriman, R. L., Toth, J. E., Zimmermann, J. E., Hertel, L. W., Andis, S. L., Dudley, D. E., Rutherford, P. G., Tanzer, L. R., and Grindey, G. B., Evaluation of new anticancer agents against the MIA Paca-2 and PANC-1 human pancreatic carcinoma xenografts.Oncol. Res., 5, 223 (1993).
Skehan, P., Storeng, R., Scudiero, D. A., Monks, A., McMahon, J., Vista, D. T., Warren, J. T., Kenny, S., and Boyd, M. R., New Colorimetric cytotoxicity assay for anticancer drug screening,J. Natl. Cancer. Inst., 82, 1107–1112 (1990).
Talbot, D. C., Smith, I. E., Nicolson, M. C., Powles, T. J., Button, D., and Walling, J., Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.J. Cancer Chemother. Pharmacol., 31, 419–422 (1993).
Taylor, C. W., Alberts, D. S., Ketcham, M. A., Satterlee, W. G., Holdsworth, M. T., Plazia, P. M., Peng, Y. M., Mccloskey, T. M., Roe, D. J., Hamilton, M., and Salmaon, S. E., Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.J. Clin. Oncol., 7, 1733–1740 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jung, SH., Kwak, SJ. Planar structural requirement at 4-position of 1-arylsulfonyl-4-phenyl-4,5-dihydro-2-imidazolones for their cytotoxicity. Arch. Pharm. Res. 20, 283–287 (1997). https://doi.org/10.1007/BF02976159
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976159